PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 14, 2026Biomaterials Science0 citations

In situ induction of multivalent PD-L1 antibody secretion to enhance cancer immunotherapy

LCLi-Li ChenSZShi-Kun ZhouSJShui-Qing Jiang

Key Points

  • To improve the efficacy of cancer immunotherapy by inducing the secretion of PD-L1 antibodies directly within tumors.
  • Utilized in situ techniques to induce antibody secretion
  • Focused on enhancing intratumoral antibody accumulation
  • Assessed immune activation levels in tumor microenvironments
  • Increased levels of PD-L1 antibodies were observed intratumorally
  • Enhanced immune activation was noted in treated tumors
  • Improved response rates to cancer therapies were indicated

Abstract

Immune checkpoint blockade (ICB) therapy has transformed cancer treatment; however, its therapeutic efficacy remains limited, largely due to insufficient intratumoral accumulation of checkpoint-blocking antibodies (e.g., anti-PD-L1) and suboptimal immune activation....

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/699011172ccff479cfe5786dhttps://doi.org/10.1039/d5bm01896j
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-bioactive poly(amino acid)-metal-organic framework nanocomposite for reinforced cascading photodynamic immunotherapy of cancer2025 · 25 citations
  2. 2Engineered nucleocytosolic vehicles for loading of programmable editors2025 · 45 citations
  3. 3Cyclic D/L-peptides based nanoparticles regulates dendritic cell maturation and enhances anti-tumor immune response2025 · 2 citations
  4. 4The biophysical requirements that govern the efficient endosomal escape of designed mini-proteins2025 · 8 citations
  5. 5PD-1 Blockade in Melanoma2016 · 10 citations